Civica Plans to Provide Insulin at No More than $30 per Vial
“The organization announced its intentions to manufacture and distribute insulins that will be available to individuals with diabetes at lower prices than those presently on the market. Civica is working with partners CivicaScript and The Civica Foundation, as well as Arnold Ventures, Beyond Type 1, Blue Cross Blue Shield Association and 12 independent BCBS companies, the Gary and Mary West Foundation, Glen Tullman Family Foundation, Intermountain Healthcare, JDRF, Kaiser Permanente, Peterson Center on Healthcare, Providence, The Leona M. and Harry B. Helmsley Charitable Trust, Transcarent and Trinity Health.
It plans to manufacture three insulins – glargine, lispro and aspart – which are interchangeable with Sanofi’s Lantus, Eli Lilly’s Humalog and Novo Nordisk’s Novolog, respectively. It will co-develop and produce the drugs, run clinical trials and file the necessary paperwork with the U.S. Food and Drug Administration. At this time, Civica plans a recommended price to the consumer of no more than $30 per vial and no more than $55 for a box of five pen cartridges. It believes it can have these versions of insulin available by 2024.”